Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00145639 · ClinicalTrials.gov registry record · Phase 2
Osteosarcoma1999-A Study Of Intensive Chemotherapy for Osteosarcoma
A Phase 2 study, sponsored by St. Jude Children's Research Hospital.
- Completed
- Registry status
- Phase 2
- Development phase
- 80
- Enrollment target
NCT00145639 is a Phase 2 study that has completed, run by St. Jude Children's Research Hospital. The registered enrollment target is 80 participants.
The verdict
NCT00145639, a Phase 2 study, has completed, sponsored by St. Jude Children's Research Hospital.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 80 participants
- Enrollment target
Study Summary
This trial (OS99) evaluates the use of ifosfamide, carboplatin, and doxorubicin in an up-front window before surgery for localized and resectable osteosarcoma. High-dose methotrexate, which may interfere with the dose-intensive delivery of other agents, is eliminated from the treatment of localized disease. The primary objective is to compare the response rate of pre-surgical chemotherapy comprised of ifosfamide, doxorubicin, and carboplatin to that obtained with ifosfamide and carboplatin in the St. Jude OS-91 trial for patients with non-metastatic resectable osteosarcoma. We hypothesize that the histologic response rate will be improved by the addition of one course of pre-operative chemotherapy on this trial compared to the previous OS-91 trial.
Interventions
- DRUG Ifosfamide, Carboplatin, Doxorubicin
- PROCEDURE Limb Sparing
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 80 participants |
| Start Date | 1999-05 |
| Est. Completion | 2006-05 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00145639
The ClinicalTrials.gov registry entry for NCT00145639 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 80 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is St. Jude Children's Research Hospital, which has 410 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Ifosfamide, Carboplatin, Doxorubicin is the first listed.
NCT00145639 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00145639 about?
NCT00145639 is a clinical study titled "Osteosarcoma1999-A Study Of Intensive Chemotherapy for Osteosarcoma". This trial (OS99) evaluates the use of ifosfamide, carboplatin, and doxorubicin in an up-front window before surgery for localized and resectable osteosarcoma. High-dose methotrexate, which may interfere with the dose-intensive delivery of other agents, is eliminated from the treatment of localized ...
What is the current status of trial NCT00145639?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 80 participants. The study started on 1999-05. Estimated completion is 2006-05.
What interventions are being tested in trial NCT00145639?
The interventions under investigation include: Ifosfamide, Carboplatin, Doxorubicin (DRUG), Limb Sparing (PROCEDURE).
Who is sponsoring clinical trial NCT00145639?
This trial is sponsored by St. Jude Children's Research Hospital, which has 410 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.